← Back to patent-cliff list
Nitrous oxide
Tier C — Watch / tradeNitrous oxide
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR
Indications (approved)：Major depressive disorder, Treatment-resistant depression, 自杀, Suicidal ideation, 精神科急救服务, 牙科焦虑症, 破坏性,冲动控制及品行障碍, 健忘症
Regional status
US
Phase II
2022-09-06
EU
Phase II
2024-06-01
China
Phase II
2024-01-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nitrous oxide?
Approved indications include: Major depressive disorder, Treatment-resistant depression, 自杀, Suicidal ideation, 精神科急救服务, 牙科焦虑症, 破坏性,冲动控制及品行障碍, 健忘症.
When does the Nitrous oxide patent expire?
No public expiry year is available for Nitrous oxide yet; this page updates once verified.
How do I get a quote for Nitrous oxide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29